Ongoing trials

75 clinical trials in progress

French Pompe disease registry

French registry for the follow-up of patients with Pompe disease and the collection of data on them.

French registry for the follow-up of patients with Pompe disease and the collection of data on them.

Code
Registre-FR-Pompe
Disease
Glycogen storage disease type II (Pompe disease)
Principal investigator
Pascal Laforet
Sponsor
Institut de Myologie
Status
Active
Public
Adults

SRK-015-005 – OPALE

A phase 2 study evaluating the pharmacokinetics, pharmacodynamics, efficacy and safety of apitegromab in participants under 2 years of age with spinal muscular atrophy.

A phase 2 study evaluating the pharmacokinetics, pharmacodynamics, efficacy and safety of apitegromab in participants under 2 years of age with spinal muscular atrophy.

Code
SRK-015-005 – OPALE
Disease
Spinal muscular atrophies
Principal investigator
Andreea Seferian
Sponsor
Scholar Rock
Status
In preparation
Public
Paediatric
Phase
Phase 2
Trial site
I-Motion Pediatric

View on ClinicalTrials.gov

International Pompe disease registry

International registry for the follow-up of patients with Pompe disease.

International registry for the follow-up of patients with Pompe disease.

Code
Registre-INT-Pompe
Disease
Glycogen storage disease type II (Pompe disease)
Principal investigator
Pascal Laforet (pour la France)
Sponsor
Sanofi
Status
Active
Public
Adults

R-SMA

A retrospective study of the natural history of the disease and real-world assessment of the effect of treatments in patients with spinal muscular atrophy.

A retrospective study of the natural history of the disease and real-world assessment of the effect of treatments in patients with spinal muscular atrophy.

Code
R-SMA
Disease
Spinal muscular atrophies
Principal investigator
Tanya Stojkovic
Sponsor
APHP
Status
Active
Public
Adults

View on ClinicalTrials.gov

UMD-EMD – Emerinopathy database

Non-interventional data collection on emerinopathies, gathering medical information and following the progression of patients with Emery-Dreifuss muscular dystrophy.

Non-interventional data collection on emerinopathies, gathering medical information and following the progression of patients with Emery-Dreifuss muscular dystrophy.

Code
UMD-EMD
Disease
Laminopathies and emerinopathies
Principal investigator
France Leturcq, Rabah Ben Yaou
Sponsor
Laboratoire de biochimie et genetique moleculaire GH Cochin + Centres de Reference des maladies neuromusculaires + Centre de recherche en myologie Institut de Myologie
Status
Ongoing
Public
Adults

NH-SMA / SMOB

Outcome measures and biomarkers in a cohort of patients with type 3 or type 4 spinal muscular atrophy (SMA).

Outcome measures and biomarkers in a cohort of patients with type 3 or type 4 spinal muscular atrophy (SMA).

Code
NH-SMA / SMOB
Disease
Spinal muscular atrophies
Principal investigator
Tanya Stojkovic
Sponsor
APHM
Status
Active
Public
Adults

View on ClinicalTrials.gov

UMD-LMNA – Laminopathy database

Non-interventional data collection on laminopathies, gathering medical information and following the progression of patients with Emery-Dreifuss muscular dystrophy.

Non-interventional data collection on laminopathies, gathering medical information and following the progression of patients with Emery-Dreifuss muscular dystrophy.

Code
UMD-LMNA
Disease
Laminopathies and emerinopathies
Principal investigator
Gisele Bonne, Rabah Ben Yaou
Sponsor
Centre de recherche en myologie Institut de Myologie + UF de Cardiogenetique et Myogenetique Moleculaire et Cellulaire
Status
Ongoing
Public
Adults

PTC-AADC-MA-406

A two-part, international, real-world observational registry of participants diagnosed with aromatic L-amino acid decarboxylase (AADC) deficiency, with or without treatment with eladocagene exuparvovec.

A two-part, international, real-world observational registry of participants diagnosed with aromatic L-amino acid decarboxylase (AADC) deficiency, with or without treatment with eladocagene exuparvovec.

Code
PTC-AADC-MA-406
Disease
AADC deficiency
Principal investigator
Claudia Ravelli
Sponsor
PTC Therapeutics
Status
Active
Public
Paediatric

UMD FHL1 – FHL1 database

Non-interventional data collection on myopathies related to FHL1 gene abnormalities, gathering medical information and following the progression of patients.

Non-interventional data collection on myopathies related to FHL1 gene abnormalities, gathering medical information and following the progression of patients.

Code
UMD-FHL1
Disease
Laminopathies and emerinopathies
Principal investigator
Gisele Bonne, Rabah Ben Yaou
Sponsor
Centre de recherche en myologie Institut de Myologie + UF de Cardiogenetique et Myogenetique Moleculaire et Cellulaire
Status
Ongoing
Public
Adults

UMD-DNM2 – Dynaminopathy databases

Non-interventional data collection on dynaminopathies, neuromuscular diseases caused by mutations in the DNM2 gene, which encodes dynamin 2, a protein involved in endocytosis and intracellular membrane trafficking as well as in the regulation of the actin and microtubule cytoskeletons.

Non-interventional data collection on dynaminopathies, neuromuscular diseases caused by mutations in the DNM2 gene, which encodes dynamin 2, a protein involved in endocytosis and intracellular membrane trafficking as well as in the regulation of the actin and microtubule cytoskeletons.

Code
UMD-DNM2
Disease
Dynaminopathies
Principal investigator
Marc Bitoun / Valerie Biancalana
Sponsor
Inserm U974, Institut de Myologie / Laboratoire de diagnostic genetique, Hopital Universitaire de Strasbourg
Status
Ongoing
Public
Adults

OPALE National Registry – Laminopathy and emerinopathy observatory

A national registry collecting data on patients with laminopathies and emerinopathies, in order to follow their progression and compare the different forms of the disease.

A national registry collecting data on patients with laminopathies and emerinopathies, in order to follow their progression and compare the different forms of the disease.

Code
OPALE-National
Disease
Laminopathies and emerinopathies
Principal investigator
Karim Wahbi (PI), Gisele Bonne, Rabah Ben Yaou (coordonnateurs operationnels)
Sponsor
Institut de Myologie
Status
Ongoing
Public
Adults, Paediatric

DYNE101-DM1-201

A randomised, placebo-controlled, multiple-ascending-dose study evaluating the safety, tolerability, pharmacodynamics, efficacy and pharmacokinetics of DYNE-101 in participants with myotonic dystrophy type 1.

A randomised, placebo-controlled, multiple-ascending-dose study evaluating the safety, tolerability, pharmacodynamics, efficacy and pharmacokinetics of DYNE-101 in participants with myotonic dystrophy type 1.

Code
DYNE101-DM1-201
Disease
Myotonic dystrophies
Principal investigator
Guillaume Bassez
Sponsor
DYNE Therapeutics
Status
Active
Public
Adults
Trial site
I-Motion Adults

View on ClinicalTrials.gov

NMD670

A phase 2a, randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of NMD670 over 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type 2.

A phase 2a, randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of NMD670 over 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type 2.

Code
NMD670
Disease
Charcot-Marie-Tooth disease
Principal investigator
Marion Masingue
Sponsor
NMD Pharma
Status
Active
Public
Adults
Phase
Phase 2
Trial site
I-Motion Adults

View on ClinicalTrials.gov

PIP4 (MEX-NM-301)

An open-label, non-comparative study to evaluate the steady-state pharmacokinetics, safety and efficacy of mexiletine in adolescents and children with myotonic disorders.

An open-label, non-comparative study to evaluate the steady-state pharmacokinetics, safety and efficacy of mexiletine in adolescents and children with myotonic disorders.

Code
PIP4 (MEX-NM-301)
Disease
Myotonic dystrophies
Principal investigator
Arnaud Isapof
Sponsor
Lupin
Status
Ongoing
Public
Paediatric
Trial site
I-Motion Pediatric

View on ClinicalTrials.gov

Mitochondrial disease registry

Prospective follow-up of a cohort of adult patients with mitochondrial diseases (observational study).

Prospective follow-up of a cohort of adult patients with mitochondrial diseases (observational study).

Code
Registre-Mitochondriopathies
Disease
Mitochondrial diseases
Principal investigator
Pascal Laforet
Sponsor
Institut de Myologie
Status
Active
Public
Adults